Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles

Abstract

The current work was carried out by the principles of quality-by-design approach to develop an optimized solid lipid nanoparticles (SLNs) formulation of diallyl disulfide (DADS) through systematic statistical study. And its antitumor activity of DADS was also evaluated on breast cancer cell lines. To understand the effect of formulation variables (critical parameters) on the responses (critical quality attributes) of SLN, a 3-factor, 3-level Box-Behnken design, was explored to predict the responses such as particle size (Y1) and % entrapment efficiency (EE) (Y2) when concentration of surfactant (X1), amount of lipid (X2), and volume of solvent (X3) were selected as independent variables. Particle size analysis revealed that all the batches were within the nanometer range. DADS was released from the SLN much more rapidly at pH 4.5 than at pH 7.4, which is a desirable characteristic for tumor-targeted drug delivery. The cytotoxicity, reactive oxygen species (ROS), determination revealed that the antitumor activity of DADS is enhanced with SLN compared to DADS-free drug, and apoptosis is the mechanism underlying the cytotoxicity. The present study indicated the remarkable potential of DADS-SLN in enhancing the anticancer effect of DADS in breast cancer cells in vitro.

RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies

“…The preparation of DADS-SLN formulation was prepared by solvent diffusion method as reported previously by our group with slight modification [18]. Palmitic acid was used as a lipid, pluronic F-68 and soya lecithin were used as surfactant and co surfactant respectively.…”

“…In our previous study, we have prepared solid lipid nanoparticles of DADS (DADS-SLN) to overcome its bioavailability problems [18]. However, selective targeting of DADS specifically to TNBC cancer cells is questionable.…”

Nanocarrier based approaches for targeting breast cancer stem cells

“…Nanocarriers offer various advantages for targeting tumours by overcoming the bioavailability issued of chemotherapeutic agents [24]. They can passively accumulate at the tumour site owing to the leaky vasculature of tumour [25]. In addition, active targeting by surface modification of suitable ligands for tumour biomarkers improves the site specificity of nanocarriers [26][27][28].…”

Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies

“…7). [8][9][10][11][22][23][24] THP-CAP-LPs augmented the expression of proapoptotic proteins and inhibited antiapoptotic protein expression…”